

# The association between CCR5, NLRC4, and AIM2 gene polymorphisms and susceptibility to tuberculosis in the Iraqi population

BILAL KHALEEL<sup>1,\*</sup>, HUDA R.S. AL-ALWANI<sup>1</sup>, AHMED ASMAR<sup>2</sup>

<sup>1</sup>Department of Microbiology, College of Medicine, University of Anbar. Ceramic Street, Ramadi 31001, Central Anbar, Iraq. Tel.: +96-47831041485,

\*email: bel21m0007@uoanbar.edu.iq

<sup>2</sup>Iraqi Ministry of Health. Al Adham Street, Baghdad, Iraq

Manuscript received: 7 February 2024. Revision accepted: 15 March 2024.

**Abstract.** Khaleel B, Al-Alwani HRS, Asmar A. 2024. The association between CCR5, NLRC4, and AIM2 gene polymorphisms and susceptibility to tuberculosis in the Iraqi population. *Biodiversitas* 25: 1022-1029. In immunological reactions against *Mycobacterium tuberculosis*, chemokines and their receptors, including CXCR3, CCR5, and RANTES, play an important role in the migration and activation of cells. The inflammasome is a multiprotein complex that serves as a master regulator of inflammation. Genetic polymorphisms contribute to individual phenotypic differences, such as disease risk and drug response. The current study was done to find the polymorphism in the CCR5, NLRC4, and AIM2 genes in our population and to look into how this polymorphism is linked to getting tuberculosis. Seventy-five tuberculosis patients participated in this study, while the control group comprised twenty-five healthy individuals. We took two milliliters of blood from the patients and the control group and placed them in an Ethylenediaminetetraacetic acid (EDTA tube), or DNA extraction. Real-time PCR was used to find changes in the genes for CCR5 (rs2227010, rs2734648, rs1799987, rs1799988, rs1800023, rs1800024), NLRC4 (C-rs479333), and AIM2 (CC-rs1103577). Some genotypes were more common in the patient group, including SNPs CCR5 (rs2227010, rs2734648, rs1799988, rs1800023, rs1800024), NLRC4 C-rs479333, and AIM2 CC-rs1103577. However, by using Two-Two cross table the genotype of SNP CCR5-rs1799987 was not significantly different between the patient and the controls. Patients also had a lot of certain alleles for the SNPs CCR5 (rs2227010, rs1799988, rs1800023, rs1800024) and NLRC4 (rs479333). However, the alleles for the SNPs CCR5 (rs2734648, rs1799987) and AIM2 CC (rs1103577) were not very different between patients and controls. This study concludes that a polymorphism in various SNPs of the CCR5, NLRC4, and AIM2 genes may be a risk factor for tuberculosis.

**Keywords:** Chemokine's receptor (CCR5), gene polymorphisms, inflammasome (NLRC4, AIM2), Iraq, *Mycobacterium tuberculosis*

## INTRODUCTION

*Mycobacterium tuberculosis* and *M. bovis* are the name of the bacterium that causes Tuberculosis (TB). Most *Mycobacterium TB* infections remain latent or undiagnosed, and only a tiny fraction of infected people develop active tuberculosis, according to Forrellad et al. (2020) and Ogishi et al. (2022). Inflammation is the immune system's first response to any danger, whether it is a disease, an irritation, or damaged cells. Chronic, or dysregulated, inflammation is a known disease initiator, Rheumatoid arthritis (Bennett et al. 2018). systemic lupus erythematosus, inflammatory bowel disease, metabolic problems, cardiovascular disease, neurodegenerative illness, and autoimmune diseases are all part of this category (Chen et al. 2018). A network of proteins is known as the inflammatory regulatory complex. Ordinary components include effector caspases, adaptor molecules, and Pattern Recognition Receptors (PRRs). Due to their PRRs and involvement in inflammasome activation, Non-Occclusive Disease (NOD)-Like Receptors (NLRs) have received the lion's share of study and attention (Davignon et al. 2023). Some examples of these are NLRP1, NLRP3, NLRC4, and many more. Inflammasomes rely on pyrin and the missing melanoma 2 (AIM2)-like receptor (AIM2), according to research by Zhou et al. (2021). A multiprotein complex called the inflammasome

is essential to the innate immune system's reaction to microbial diseases, such as Tuberculosis. NLRC4 and AIM2, two inflammasome family members, have been linked to tuberculosis susceptibility (Ma et al. 2021). An intracellular sensor called NLRC4 initiates the inflammasome complex when it detects bacterial flagellin. According to a number of research, NLRC4 polymorphisms may be linked to TB susceptibility (De Lima et al. 2020). For instance, a study on the NLRC4 gene's CC genotype of the rs385076 C>T polymorphism indicated a higher risk of tuberculosis in those with this genotype in a Chinese population. A different study on a population in South Africa discovered that specific NLRC4 haplotypes were linked to a higher incidence of tuberculosis (Torres et al. 2019). An important part of the host's immune response to TB is the activation of T helper 1 (Th1) cells, which leads to more CCR5 being expressed (Blanco et al. 2021). Infections with TB are also associated with significantly increased CCR5 expression. Pulmonary TB patients show significantly higher levels of CCR5 expression compared to healthy controls (Liu et al. 2021). The ligand-CCR5 interaction has far-reaching effects on T cell activation and migration, the immunological response to TB infection, and other related processes. Research carried out by Fisher et al. (2021) indicates that effector CD8+ T cells without CCR5 transmigrate from the pulmonary vascular system to the interstitial compartment

at a rate about 50% lower than that of CD8+ T cells with CCR5 wild-type. Despite CCR5's critical role in resistance to *TB*, some variants in the gene have been associated with tuberculosis infections and disease development (Carpenter et al. 2014).

Barletta-Naveca et al. (2018) have studied the inherited vulnerability to TB. Fernandes et al. (2020) found that variations in inflammasome physiological activity that run in families may impact susceptibility, severity, and outcome in tuberculosis. According to de Lima et al. (2016), two Single-Nucleotide Polymorphisms (SNPs)-P2X7 (rs2230911) and NLRP3 (rs10754558)-are connected to TB. There is a connection between NLRP3 (rs10754558) and protection against pulmonary TB. A study by Abate et al. (2019) found that the SNP (rs35829419) has been associated with tuberculosis susceptibility in the Ethiopian population, whereas no significant associations were found with the P2X7 (rs2230911) and CARD8 (rs2043211) SNPs. SNPs are linked to tuberculosis susceptibility. The interaction of cytosolic NLR (leucine-rich repeat-containing, nucleotide-binding, and oligomerization domain) receptors, namely NLRP3 and NLRC4, with ligands enhances the function of the inflammasome. According to Zhang et al. (2017), studies conducted on dendritic cells and macrophages infected with *Mycobacterium tuberculosis* in vitro have primarily implicated NLRP3 in inflammasome activation. AIM2 lacks the HIN-200 DNA-binding protein necessary for cytosolic recognition of dsDNA, as noted by Kopitar-Jerala (2017). This protein has been extensively studied. This study aims to investigate whether mutations in the CCR5, NLRC4, or AIM2 genes are associated with tuberculosis risk in our population in Iraq.

## MATERIALS AND METHODS

The study received approval from the National Center of Tuberculosis, Iraqi Ministry of Health, and the approval committee of the University of Anbar, Iraq. All participants provided informed written consent before sample collection. Based on the ethics of research, all the patients and control group gave their consent for taking the blood and sputum samples.

The names of people identified with tuberculosis were selected, and they numbered (100). 75 patients with TB infections (pulmonary and extrapulmonary). Patients enrolled in the tuberculosis center were clinically diagnosed and included in the study. Twenty-five healthy individuals control without a history of infection made up the control group, were selected from our healthy population outside the hospital. All of the samples were from people in Baghdad and Ramadi City, Iraq. From August 2022 through January 2023, the samples were gathered under the supervision of medical specialists.

### Procedures

The health conditions of the patients A blood anticoagulant tube was used to take two milliliters of peripheral venous blood. The presence of EDTA-K<sub>2</sub>, or ethylenediamine tetraacetic acid, is included in this tube.

For future reference, we stored the material at 4°C and extracted the DNA using the EasyPure® Genomic DNA Kit (TransGen, biotech. EE101-01) according to the manufacturer's instructions.

Prior to utilizing TE buffer as a blank solution, a Nanodrop spectrophotometer OneC (Thermo Fisher Scientific) equipped with basic computer software for data control and recording was employed to assess the quality of DNA samples. Two microliters of the isolated DNA were added for concentration measurement, yielding concentrations ranging from 63 to 84 ng/μL. Furthermore, the absorbance of DNA samples was measured at wavelengths of 260 and 280 nm using the Nanodrop spectrophotometer to ascertain purity. The A260/A280 ratio falling between 1.7 and 1.9 confirms the absence of contaminants in the DNA samples. We used Reverse Transcription and quantitative Polymerase Chain Reaction (qRT-PCR) to find out how much of the CCR5 polymorphism there was.

Utilizing the TransStart® Top Green qPCR Super Mix kit and the measurement of the threshold cycle (Ct), the levels and fold variations of the CCR5 polymorphism, NLRC4 C, and AIM2 CC genes were evaluated. It was necessary to repeat each response twice. The quantitative Real-Time-PCR (qRT-PCR) was performed using a QIAGEN Rotor gene Q real-time PCR system (Germany). The primers used for detection of gene polymorphisms in this study were instructed in the following Table 1.

### Data analysis

Regarding statistical analysis, data were analyzed using SPSS for Windows, version 26 (SPSS Inc., Chicago, Illinois, United States). Results were presented as means and Standard Deviations (SD). The Shapiro-Wilk normality test was employed to verify the normal distribution of the data under study. Chi-square test was used to significantly compare between percentage (0.05 and 0.01 probability). Estimate of Odd ratio and CI in this study. WINPEPI and SPSS program were used to detect the genotyping.

### Adds ratio

An odds ratio will be equal to 1, there is no connection between the SNP to the trait or genetic condition. In the other words, if the same percent of people in two groups have the SNP. An odds ratio greater than 1 means that having the SNP makes someone more likely to have the condition. It was found more often in the ALS group. We would consider that SNP a risk factor for that condition. An odds ratio of less than 1, means having the SNP makes some one less likely to have the condition. This would make the SNP protective factor for that condition.

### Hardy Weinberg equilibrium of SNP

By comparing observed and expected value. If the p value is less than 0.05 then it implies is a deviation and you should look in to the causes of it. Deviance from HWE in control subjects may result from genotyping errors, from stratification of the control samples. Note: Be careful to test to test HWE on control only. Do not test on patients as a variant strongly associated with disease would sometime show deviance from HWE in patients' samples.

**Table 1.** Primers used for detection of gene polymorphisms in this study

| Primer              |   | Sequence (5'→3' direction) | Primer size (bp) | Product size bp | Ta (°C) |
|---------------------|---|----------------------------|------------------|-----------------|---------|
| CCR5 Polymorphism   |   |                            |                  |                 |         |
| rs2227010 (A> G)    | F | TGAGATTTTCAGATGTCACCA      | 21               | 48              | 58      |
|                     | R | ACAGTCATATCAAGCTCTCTT      | 21               |                 |         |
| rs2734648 (T>G)     | F | CCCGTGAGCCCATAGTTAAAA      | 21               | 84              | 58      |
|                     | R | ACAGATGCTCACCACCCAAT       | 20               |                 |         |
| rs1799987 (G>A)     | F | TTGGGGTGGGATAGGGGATA       | 20               | 74              | 58      |
|                     | R | GGGGATCCTGGACTTCACAT       | 20               |                 |         |
| rs1799988 (T>G)     | F | CAAAATAATCCAGTGAGAAAAGC    | 23               | 110             | 60      |
|                     | R | GAAAAGAATCAGAGAACAGTTC     | 22               |                 |         |
| rs1800023 (G >A)    | F | AGCCCGTAAATAAACCTTCAGAC    | 23               | 104             | 60      |
|                     | R | AGTGTATTGAAGGCGAAAAAGA     | 21               |                 |         |
| rs1800024 (C> T)    | F | AAGACTTTACAGGAAACCCA       | 20               | 104             | 60      |
|                     | R | TCCAAACTGTGACCCTTTCC       | 20               |                 |         |
| NLRC4 C (rs479333)  |   |                            |                  |                 |         |
| Forward             |   | ACTTGGGAGATTGGATGGACT      | 21               | 98              | 58      |
| Reverse             |   | GGAAACTCACTCTTGTTGCT       | 20               |                 |         |
| AIM2 CC (RS1103577) |   |                            |                  |                 |         |
| Forward             |   | ACTTCCACTACCTATCCCCT       | 20               | 103             | 58      |
| Reverse             |   | GCAAAGGGAAAAGGAGAGCC       | 20               |                 |         |

Note: If the p-value<0.05 that mean there is significant different or more prevalent or associated with disease based on each SNP result

## RESULTS AND DISCUSSION

### Results

Table 2 demonstrates that patients often have the genotypes GG and GA, as well as the alleles G and A, related to the CCR5 SNP (rs2227010).

There is a high prevalence of genotype GG and GT in patients when it comes to the CCR5-rs2734648 SNP. Table 3 shows that there is no statistically significant difference in the G and T alleles between the control group and the patients.

As shown in Table 4, there is no statistically significant difference in the genotypes and allele frequencies for the CCR5-rs1799987 SNP between the control group and the patients.

Table 5 shows that for the SNP CCR5-rs1799988, there was a high prevalence of the TT genotype and C, T alleles in the patients.

According to Table 6, a large percentage of patients had the AG, GG genotype and the A, G alleles for the SNP CCR5-rs1800023.

The result shows a high frequency of CC, CT, TT genotype, and C, T Alleles in patients for the SNP CCR5-rs1800024 as indicated by Table 7.

Table 8 displays the results for the NLRC4 C-rs479333 single-nucleotide polymorphism, which reveals that patients often had the AA genotype and the C and A alleles.

The results show a high frequency of genotype TA in the patients, while there is no significant difference in T, A alleles between patients and control, for the SNP of AIM2 CC-RS1103577 as indicated by Table 9.

### Discussion

*Mycobacterium tuberculosis* is an infectious disease that poses a significant threat to human life. To comprehend

why only a small percentage of individuals, ranging from 5% to 10%, exhibit symptoms of active TB infection (Klinkenberg et al. 2023). Researchers are striving to pinpoint associated risk factors. Understanding these factors is crucial for developing effective TB vaccines, immunotherapies, and unraveling the complexities of outcomes following *M. tuberculosis* infection, be it active or latent TB illness. Gathering data on host immune responses to *M. tuberculosis* infections is essential for these endeavors. There is substantial evidence suggesting that host genetics influence the progression of tuberculosis (Kauffman et al. 2018). CCR5 has been identified as playing a pivotal role in immunological responses to *Mycobacterium TB* infection, regulating T cell activation and macrophage recruitment (Liu et al. 2021). Various factors, both intrinsic and extrinsic to the human body, impact the immunological response to *Mycobacterium TB*. Despite this, little is understood about the intricate cascade of events from early infections to tuberculosis development. Following the elucidation of the diverse functions of inflammasomes, research has focused extensively on genetic variants within genes involved in assembling the inflammasome multiprotein complex. This pursuit aims to shed light on why certain individuals remain asymptomatic while others are predisposed to illness. During the initial stages of infection, the innate immune response assumes a pivotal role. According to the results, the ((GG, GA), (GG, GT), (TT), (AG, GG), (CC, CT, TT)) genotype is associated with a high frequency of certain CCR5 SNPs, including (rs2227010, rs2734648, rs1799988, rs1800023, rs1800024). This study's findings demonstrate that certain single-nucleotide polymorphisms (SNPs) in the CCR5 gene are associated with high frequencies of the ((G, A),(C, T),(A, G), and (C, T)) alleles in patients, namely (rs2227010, rs1799988, rs1800023, rs1800024).

**Table 2.** Frequency of genotype and CCR5 SNP rs2227010 gene alleles in patients and controls

| CCR5-Rs2227010   |                       |                   |            |                |                |         |
|--|-----------------------|-------------------|------------|----------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                       |                   |            |                |                |         |
| Genotype Rs10  | Patients no. () + (%) | Control no. + (%) | Odds ratio | 95% CI         | p-value        |         |
| GG   | 34 (45.33%)           | 23 (92.00%)       | 0.07       | 0.01 to 0.29   | 0.0001         |         |
| GA   | 32 (42.67%)           | 1 (4.00%)         | 17.86      | 3.01 to 381.87 | 0.0001         |         |
| AA   | 9 (12.00%)            | 1 (4.00%)         | 3.27       | 0.49 to 75.18  | 0.3            |         |
| Alleles frequency of SNP                               |                       |                   |            |                |                |         |
| Alleles Rs10   | Patients no.          | Control No.       | Odds ratio | 95% CI         | p-value        |         |
| G  | 100 (66.67%)          | 47 (94.00%)       | 0.13       | 0.03 to 0.39   | 0.0001         |         |
| A  | 50 (33.33%)           | 3 (6.00%)         | 7.83       | 2.54 to 32.92  | 0.0001         |         |
| Hardy Weinberg equilibrium of SNP                      |                       |                   |            |                |                |         |
| Rs10   |                       | GG                | GA         | AA             | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype     | 34                | 32         | 9              | 0.12           | 0.9     |
|  | Expected genotype     | 33.33             | 33.33      | 8.33           |                |         |
| Control group  | Observed genotype     | 23                | 1          | 1              | 10.41          | 0.005   |
|  | Expected genotype     | 22.09             | 2.82       | 0.09           |                |         |

Note: \*The mean difference is significant at p-value&lt;0.05

**Table 3.** Genotype and alleles frequency of CCR5 SNP rs2734648 gene in patients and controls

| CCR5-rs2734648   |                       |                   |            |                |                |         |
|--|-----------------------|-------------------|------------|----------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                       |                   |            |                |                |         |
| Genotype Rs48  | Patients no. () + (%) | Control no. + (%) | Odds ratio | 95% CI         | p-value        |         |
| GG   | 24 (32.00%)           | 14 (56.00%)       | 0.37       | 0.14 to 0.95   | 0.04           |         |
| GT   | 27 (36.00%)           | 1 (4.00%)         | 13.5       | 2.27 to 290.22 | 0.001          |         |
| TT   | 24 (32.00%)           | 10 (40.00%)       | 0.71       | 0.28 to 1.86   | 0.4            |         |
| Alleles frequency of SNP                               |                       |                   |            |                |                |         |
| Alleles Rs48   | Patients no.          | Control no.       | Odds ratio | 95% CI         | p-value        |         |
| G  | 75 (50.00%)           | 29 (58.00%)       | 0.72       | 0.38 to 1.39   | 0.3            |         |
| T  | 75 (50.00%)           | 21 (42.00%)       | 1.38       | 0.72 to 2.66   | 0.3            |         |
| Hardy Weinberg equilibrium of SNP                      |                       |                   |            |                |                |         |
| Rs48   |                       | GG                | GT         | TT             | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype     | 24                | 27         | 24             | 5.88           | 0.05    |
|  | Expected genotype     | 18.75             | 37.5       | 18.75          |                |         |
| Control group  | Observed genotype     | 14                | 1          | 10             | 21.06          | 0.0001  |
|  | Expected genotype     | 8.41              | 12.18      | 4.41           |                |         |

Note: \*The mean difference is significant at p-value&lt;0.05

**Table 4.** Genotype and alleles frequency of CCR5 SNP rs1799987 gene in patients and controls

| CCR5-rs1799987   |                       |                   |            |               |                |         |
|--|-----------------------|-------------------|------------|---------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                       |                   |            |               |                |         |
| Genotype Rs87  | Patients no. () + (%) | Control no. + (%) | Odds ratio | 95% CI        | p-value        |         |
| GG   | 29 (38.67%)           | 13 (52.00%)       | 0.58       | 0.23 to 1.47  | 0.2            |         |
| GA   | 42 (56.00%)           | 11 (44.00%)       | 1.62       | 0.64 to 4.12  | 0.3            |         |
| AA   | 4 (5.33%)             | 1 (4.00%)         | 1.35       | 0.16 to 34.78 | 0.7            |         |
| Alleles frequency of SNP                               |                       |                   |            |               |                |         |
| Alleles Rs87   | Patients no.          | Control no.       | Odds ratio | 95% CI        | p-value        |         |
| G  | 100 (66.67%)          | 37 (74.00%)       | 0.70       | 0.33 to 1.43  | 0.3            |         |
| A  | 50 (33.33%)           | 13 (26.00%)       | 1.42       | 0.70 to 2.99  | 0.3            |         |
| Hardy Weinberg equilibrium of SNP                      |                       |                   |            |               |                |         |
| Rs87   |                       | GG                | GA         | AA            | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype     | 29                | 42         | 4             | 5.07           | 0.07    |
|  | Expected genotype     | 33.33             | 33.33      | 8.33          |                |         |
| Control group  | Observed genotype     | 13                | 11         | 1             | 0.51           | 0.7     |
|  | Expected genotype     | 13.69             | 9.62       | 1.69          |                |         |

Note: \*The mean difference is significant at p-value&lt;0.05

**Table 5.** Frequency of genotype and alleles of CCR5 SNP rs1799988 gene in patients and controls

| CCR5-rs1799988   |                   |             |            |               |                |         |
|--|-------------------|-------------|------------|---------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                   |             |            |               |                |         |
| Genotype Rs88  | Patients no.      | Control no. | Odds ratio | 95% CI        | p-value        |         |
| CC   | 39 (52.00%)       | 16 (64.00%) | 0.61       | 0.23 to 1.56  | 0.3            |         |
| CT   | 10 (13.33%)       | 6 (24.00%)  | 0.49       | 0.16 to 1.63  | 0.1            |         |
| TT   | 26 (34.67%)       | 3 (12.00%)  | 3.89       | 1.13 to 17.49 | 0.03           |         |
| Alleles frequency of SNP                               |                   |             |            |               |                |         |
| Alleles Rs88   | Patients no.      | Control no. | Odds ratio | 95% CI        | p-value        |         |
| C  | 88 (58.67%)       | 38 (76.00%) | 0.45       | 0.21 to 0.92  | 0.02           |         |
| T  | 62 (41.33%)       | 12 (24.00%) | 2.23       | 1.09 to 4.75  | 0.02           |         |
| Hardy Weinberg equilibrium of SNP                      |                   |             |            |               |                |         |
| Rs88   |                   | CC          | CT         | TT            | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype | 39          | 10         | 26            | 39.43          | 0.0001  |
|  | Expected genotype | 25.81       | 36.37      | 12.81         |                |         |
| Control group  | Observed genotype | 16          | 6          | 3             | 2.93           | 0.2     |
|  | Expected genotype | 14.44       | 9.12       | 1.44          |                |         |

Note: \*The mean difference is significant at p-value<0.05

**Table 6.** Frequency of genotype and Alleles of CCR5 SNP rs1800023 gene in patients and controls

| CCR5-rs1800023   |                   |             |            |               |                |         |
|--|-------------------|-------------|------------|---------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                   |             |            |               |                |         |
| Genotype RS23  | Patients no.      | Control no. | Odds ratio | 95% CI        | p-value        |         |
| AA   | 11 (14.67%)       | 5 (20.00%)  | 0.69       | 0.22 to 2.44  | 0.4            |         |
| AG   | 56 (74.67%)       | 6 (24.00%)  | 9.33       | 3.24 to 28.21 | 0.0001         |         |
| GG   | 8 (10.67%)        | 14 (56.00%) | 0.09       | 0.03 to 0.28  | 0.0001         |         |
| Alleles frequency of SNP                               |                   |             |            |               |                |         |
| Alleles Rs23   | Patients no.      | Control no. | Odds ratio | 95% CI        | p-value        |         |
| A  | 78 (52.00%)       | 16 (32.00%) | 2.30       | 1.17 to 4.60  | 0.01           |         |
| G  | 72 (48.00%)       | 34 (68.00%) | 0.43       | 0.22 to 0.85  | 0.01           |         |
| Hardy Weinberg equilibrium of SNP                      |                   |             |            |               |                |         |
| Rs23   |                   | GG          | GA         | AA            | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype | 11          | 56         | 8             | 18.43          | 0.0001  |
|  | Expected genotype | 20.28       | 37.44      | 17.28         |                |         |
| Control group  | Observed genotype | 5           | 6          | 14            | 5.03           | 0.08    |
|  | Expected genotype | 2.56        | 10.88      | 11.56         |                |         |

Note: \*The mean difference is significant at p-value<0.05

**Table 7.** Frequency of genotype and Alleles of CCR5 SNP rs1800024 gene in patients and controls

| CCR5-rs1800024   |                   |             |            |                |         |         |
|--|-------------------|-------------|------------|----------------|---------|---------|
| Genotype frequencies of SNP among patients and control |                   |             |            |                |         |         |
| Genotype RS24  | Patients no.      | Control no. | Odds ratio | 95% CI         | p-value |         |
| CC   | 28 (37.33%)       | 22 (88.00%) | 0.08       | 0.02 to 0.28   | 0.0001  |         |
| CT   | 24 (32.00%)       | 2 (8.00%)   | 5.41       | 1.32 to 36.03  | 0.01    |         |
| TT   | 23 (30.67%)       | 1 (4.00%)   | 10.62      | 1.77 to 229.58 | 0.004   |         |
| Alleles frequency of SNP                               |                   |             |            |                |         |         |
| Alleles Rs24   | Patients no.      | Control no. | Odds ratio | 95% CI         | p-value |         |
| C  | 80 (53.33%)       | 46 (92.00%) | 0.10       | 0.03 to 0.27   | 0.0001  |         |
| T  | 70 (46.67%)       | 4 (8.00%)   | 10.06      | 3.67 to 34.00  | 0.0001  |         |
| Hardy Weinberg equilibrium of SNP                      |                   |             |            |                |         |         |
| Rs24   |                   | CC          | CT         | TT             | X2      | p-value |
| Patients group   | Observed genotype | 28          | 24         | 23             | 9.57    | 0.008   |
|  | Expected genotype | 21.33       | 37.33      | 16.33          |         |         |
| Control group  | Observed genotype | 22          | 2          | 1              | 5.21    | 0.07    |
|  | Expected genotype | 21.16       | 3.68       | 0.16           |         |         |

Note: \*The mean difference is significant at p-value<0.05

**Table 8.** Frequency of genotype and Alleles of NLRC4 C SNP rs479333 gene in patients and controls

| NLRC4 C-rs479333                                       |                   |              |             |            |               |                |         |
|--|-------------------|--------------|-------------|------------|---------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                   |              |             |            |               |                |         |
| Genotype Rs33  |                   | Patients no. | Control no. | Odds ratio | 95% CI        | p-value        |         |
| CC   |                   | 31 (41.33%)  | 14 (56.00%) | 0.55       | 0.22 to 1.40  | 0.2            |         |
| CA   |                   | 21 (28.00%)  | 8 (32.00%)  | 0.83       | 0.31 to 2.31  | 0.7            |         |
| AA   |                   | 23 (30.67%)  | 3 (12.00%)  | 3.24       | 0.94 to 14.67 | 0.05           |         |
| Alleles frequency of SNP                               |                   |              |             |            |               |                |         |
| Alleles Rs33   |                   | Patients no. | Control no. | Odds ratio | 95% CI        | p-value        |         |
| C  |                   | 83 (55.33%)  | 36 (72.00%) | 0.48       | 0.23 to 0.96  | 0.03           |         |
| A  |                   | 67 (44.67%)  | 14 (28.00%) | 2.08       | 1.04 to 4.26  | 0.03           |         |
| Hardy Weinberg equilibrium of SNP                      |                   |              |             |            |               |                |         |
| Rs33   |                   |              | CC          | CA         | AA            | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype |              | 31          | 21         | 23            | 14.09          | 0.0009  |
|  | Expected genotype |              | 22.96       | 37.07      | 14.96         |                |         |
| Control group  | Observed genotype |              | 14          | 8          | 3             | 1.06           | 0.5     |
|  | Expected genotype |              | 12.96       | 10.08      | 1.96          |                |         |

Note: \*The mean difference is significant at p-value<0.05

**Table 9.** Frequency of genotype and Alleles of AIM2 CC SNP rs1103577 gene in patients and controls

| AIM2 CC-RS1103577                                      |                   |             |            |                |                |         |
|--|-------------------|-------------|------------|----------------|----------------|---------|
| Genotype frequencies of SNP among patients and control |                   |             |            |                |                |         |
| Genotype Rs77  | Patients no.      | Control no. | Odds ratio | 95% CI         | p-value        |         |
| TT   | 33 (44.00%)       | 7 (28.00%)  | 0.02       | 0.76 to 5.71   | 0.2            |         |
| TA   | 28 (37.33% )      | 17 (68.00%) | 0.28       | 0.10 to 0.74   | 0.008          |         |
| AA   | 14 (18.67%)       | 1 (4.00%)   | 5.51       | 0.88 to 122.19 | 0.07           |         |
| Alleles frequency of SNP                               |                   |             |            |                |                |         |
| Alleles Rs77   | Patients no.      | Control no. | Odds ratio | 95% CI         | p-value        |         |
| T  | 94 (62.67%)       | 31 (62.00%) | 1.03       | 0.52 to 1.99   | 0.9            |         |
| A  | 56 (37.33%)       | 19 (38.00%) | 0.97       | 0.50 to 1.91   | 0.9            |         |
| Hardy Weinberg equilibrium of SNP                      |                   |             |            |                |                |         |
| Rs77   |                   | TT          | TA         | AA             | X <sup>2</sup> | p-value |
| Patients group   | Observed genotype | 33          | 28         | 14             | 3.06           | 0.2     |
|  | Expected genotype | 29.45       | 35.09      | 10.45          |                |         |
| Control group  | Observed genotype | 7           | 17         | 1              | 4.909          | 0.08    |
|  | Expected genotype | 9.61        | 11.78      | 3.61           |                |         |

Note:\*The mean difference is significant at p-value<0.05

The study also observed no statistically significant difference in the genotypes or allele frequencies of the CCR5-rs1799987 SNP between the control group and the patients. Similarly, for the CCR5 SNP, rs2734648, there was no statistically significant difference in the G and T alleles between the patient and control groups. A notable correlation between TB recurrence and rs2734648 was identified. Mutations in CCR5 have been demonstrated to alter chemokine responses, particularly in how the receptor binds to ligands (Liu et al. 2021). Among tuberculosis patients, the PTB group exhibited a significantly higher allelic rs2734648-G frequency in the recessive inheritance model compared to the control group, as reported by Shuyuan Liu et al. (2021). Individuals carrying rs2734648-GG were found to have a 2.382-fold increased risk of PTB exposure (Liu et al. 2021). Additionally, according to their findings, under a recessive inheritance scenario, rs1799987-AA increases the likelihood of PTB susceptibility. The variant rs1799987 (2459A>G) affects CCR5 production, as

outlined by Jasinska et al. (2022). In vitro studies have shown that rs1799987-G exhibits a 45% reduction in promoter activity compared to rs1799987-A. The CCR5 promoter demonstrates significant linkage disequilibrium, and investigations into promoter haplotypes in relation to tuberculosis susceptibility have only recently begun (Kouhpayeh et al. 2016). It is possible that other receptors with overlapping specificities may fulfill similar functions as CCR5, which could explain the lack of association with the CCR5 polymorphism. The function of macrophage inflammatory protein-1 alpha (MIP-1 $\alpha$ /CCL3) involves interaction with receptors CCR1 and CCR3 on various immune cells. Mice lacking CCR5 are capable of forming granulomas when infected with Mycobacterium TB, maintaining infection control, and initiating a Th1 response (Domingo-Gonzalez et al. 2016). Promoter SNPs are crucial for CCR5-mediated protection against TB. However, it has not been demonstrated that SNP associations with diseases are consistent across different populations.

The dominant allele Rs2734648-G is present in almost every human population on Earth. This includes almost every South Asian, European, American, and African person. To learn how rs2227010 and rs1800024 influence *M. tuberculosis* infection and TB progression, more functional studies are required.

Compared to other allelic combinations of rs1799987/rs1799988, rs1799987-A/rs1799988-C boosts CCR5 activity as a promoter by 45%, according to subsequent authors (Jasinska et al. 2022). Li et al. (2005) found that the rs1799988 C-to-T mutation, which leads to a reduction in CCR5 expression, is associated with a slower course of Acquired Immunodeficiency Syndrome (AIDS). Different from the other two CCR5-rs1799988 genotypes, rs1799988-CC carriers have more CCR5 transcription on CD4+ cells, CD4+ monocytes, and peripheral blood mononuclear cells (PBMCs).

Han Chinese people infected with *Mycobacterium tuberculosis* (*Mtb*) have eight different variations in the promoter region of the CCR5 gene. The rs1799987-AA and rs2734648-G genotypes were linked to an increased risk of TB, or pulmonary tuberculosis, at both the single and double dose levels. Chromosome 5 variations: rs2227010A, rs2734648G, rs2856758A, rs1799987G, rs1799988T, rs1800023G, rs41469351C, and rs1800024C. Analysis of the eight variations' haplotypes showed an elevated risk of tuberculosis in the lungs and TB vulnerability (Harishankar et al. 2018). The promoter polymorphism of the CCR5 gene was shown to be associated with pulmonary TB and its development in the Iraqi population, according to this research. Patients in Iraq who had contracted *Mtb* were examined for these variations. Those who had the rs2227010, rs2734648, rs1799988, rs1800023, or rs1800024 genotypes were more likely to be susceptible to TB or asthma.

Patients with the (AA) genotype and (C, A) alleles are more likely to have the NLRC4 C-rs479333 SNP, according to this research. On top of that, the study discovered that a lot of patients had the (TA, AA) genotype for the AIM2 CC-rs1103577 SNP. There was no significant difference in the frequency of the alleles for this SNP between the patients and the controls.

According to research by De Lima et al. (2020), extra-pulmonary tuberculosis is associated with at least one NLRC4 C (rs479333) allele, which indicates a significant increase in tuberculosis susceptibility. In regions where TB is prevalent, NLRC4 is linked to the outcome of the disease (De Lima et al. 2020). People with extra-pulmonary TB were less likely than people with pulmonary illness to have the functional mutation lacking rs479333 in the NLRC4 gene (49% of those who had it).

The risk of getting pulmonary TB was shown to be greater in individuals with the AIM2 CC (rs1103577) genotype compared to non-carriers, according to research by de Andrade Figueira et al. (2021). A decreased risk of the CTSB gene (rs1692816) was associated with extrapulmonary symptoms. The association between Tuberculosis (TB) protection and a single nucleotide variation (SNV) in AIM2 (rs1103577) was found by Yan et al. (2018). Immunological studies in *Mus musculus* (mice)

have shown that AIM2 has a novel protective function against *Mycobacterium tuberculosis* infection. It is thought that the AIM2-inflammasome and NLRP3 are crucial in host defence against mycobacteria. Multiple studies have shown that the AIM2-inflammasome is involved in mycobacterial infection. Macrophages infected with the pathogenic strain of *Mycobacterium bovis* generated mature IL-1 $\beta$  and activated the AIM2-inflammasome (Yang et al. 2013; de Andrade Figueira et al. 2021). When it came to the correlation between AIM2 and NLRC4 and the increased risk of TB development, this research was in line with other studies.

Accordingly, further studies with larger sample sizes of people from different demographics are necessary. Furthermore, as previously stated, SNP combinations have a pivotal role in tuberculosis susceptibility and progression.

In conclusion, the genetic variation in one or more SNPs of the CCR5, NLRC4, and AIM2 genes in Iraq population may be considered a risk factor for individuals to be susceptible to *Mycobacterium tuberculosis*. The probable role of CCR5, NLRC4 and AIM2 involved in immune response against *Mycobacterium tuberculosis* indicates that any genetic variation in above-mentioned genes may be involved in susceptibility to tuberculosis.

## REFERENCES

- Abate E, Blomgran R, Verma D, Lerm M, Fredrikson M, Belayneh M, Söderkvist P, Stendahl O, Schön T. 2019. Polymorphisms in CARD8 and NLRP3 are associated with extrapulmonary TB and poor clinical outcome in active TB in Ethiopia. *Sci Rep* 9 (1): 3126. DOI: 10.1038/s41598-019-40121-8.
- Barletta-Naveca RH, Naveca FG, de Almeida VA, Porto JIR, da Silva GAV, Ogusku MM, Sadahiro A, Ramasawmy R, Boechat AL. 2018. Toll-like receptor-1 single-nucleotide polymorphism 1805T/G is associated with predisposition to multibacillary tuberculosis. *Front Immunol* 9: 1455. DOI: 10.3389/fimmu.2018.01455.
- Bennett JM, Reeves G, Billman GE, Sturmberg JP. 2018. Inflammation-nature's spond to all types of challenges: Implications for understanding and managing "the epidemic" of chronic diseases. *Front Med* 5: 316. DOI: 10.3389/fmed.2018.00316.
- Blanco R, de Cedron MG, Gámez-Reche L, Martín-Leal A, González-Martín A, Lacalle RA, de Molina AR, Mañes S. 2021. The chemokine receptor CCR5 links memory CD4+ T cell metabolism to T cell antigen receptor nanoclustering. *Front Immunol* 12: 722320. DOI: 10.3389/fimmu.2021.722320.
- Carpenter D, Taype C, Goulding J, Levin M, Eley B, Anderson S, Shaw M-A, Armour JAL. 2014. CCL3L1 copy number, CCR5 genotype and susceptibility to tuberculosis. *BMC Med Genet* 15: 1-8. DOI: 10.1186/1471-2350-15-5.
- Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. 2018. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget* 9: 7204-7218. DOI: 10.18632/oncotarget.23208.
- Davignon G, Cagliero J, Guentas L et al. 2023. Leptospirosis: Toward a better understanding of the environmental lifestyle of *Leptospira*. *Front Water* 5: 1195094. DOI: 10.3389/frwa.2023.1195094.
- de Andrade Figueira MB, de Lima DS, Boechat AL, do Nascimento Filho MG, Antunes IA, da Silva Matsuda J, de Albuquerque Ribeiro TR, Felix LS, Gonçalves ASF, da Costa AG, Ramasawmy R, Pontillo A, Ogusku MM, Sadahiro A. 2021. Single-nucleotide variants in the AIM2-absent in melanoma 2 gene (rs1103577) associated with protection for tuberculosis. *Front Immunol* 12: 604975. DOI: 10.3389/fimmu.2021.604975.
- De Lima DS, Bomfim CCB, Leal VNC, Reis EC, Soares JLS, Fernandes FP, Amaral EP, Loures FV, Ogusku MM, D'Imperio Lima MR, Sadahiro A, Pontillo A. 2020. Combining host genetics and functional analysis to depict Inflammasome contribution in tuberculosis

- susceptibility and outcome in endemic areas. *Front Immunol* 11: 550624. DOI: 10.3389/fimmu.2020.550624.
- De Lima DS, Ogusku MM, Sadahiro A, Pontillo A. 2016. Inflammasome genetics contributes to the development and control of active pulmonary tuberculosis. *Infect Genet Evol* 41: 240-244. DOI: 10.1016/j.meegid.2016.04.015.
- Domingo-Gonzalez R, Prince O, Cooper A, Khader SA. 2016. Cytokines and chemokines in *Mycobacterium tuberculosis* infection. *Microbiol Spectr* 4: tbtb2-0018-2016. DOI: 10.1128/microbiolspec.tbtb2-0018-2016.
- Fernandes FP, Leal VNC, de Lima DS, Reis EC, Pontillo A. 2020. Inflammasome genetics and complex diseases: A comprehensive review. *Eur J Hum Genet* 28 (10): 1307-1321. DOI: 10.1038/s41431-020-0631-y.
- Fisher E, Padula L, Podack K, O'Neill K, Seavey MM, Jayaraman P, Jasuja R, Srbo N. 2021. Induction of SARS-CoV-2 protein S-specific CD8+ T cells in the lungs of gp96-Ig-S vaccinated mice. *Front Immunol* 11: 602254. DOI: 10.3389/fimmu.2020.602254.
- Forrellad MA, Blanco FC, de Villegas RMD, Vázquez CL, Yaneff A, García EA, Gutierrez MG, Durán R, Villarino A, Bigi F. 2020. Rv2577 of *Mycobacterium tuberculosis* is a virulence factor with dual phosphatase and phosphodiesterase functions. *Front Microbiol* 11: 570794. DOI: 10.3389/fmicb.2020.570794.
- Harishankar M, Selvaraj P, Bethunaickan R. 2018. Influence of genetic polymorphism towards pulmonary tuberculosis susceptibility. *Front Med* 5: 213. DOI: 10.3389/fmed.2018.00213.
- Jasinska AJ, Pandrea I, Apetrei C. 2022. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: A prototypic love-hate affair. *Front Immunol* 13: 835994. DOI: 10.3389/fimmu.2022.835994.
- Kauffman KD, Sallin MA, Sakai S, Kamenyeva O, Kabat J, Weiner D, Sutphin M, Schimel D, Via L, Barry 3<sup>rd</sup> CE, Wilder-Kofie T, Moore I, Moore R, Barber DL. 2018. Defective positioning in granulomas but not lung-homing limits CD4 T-cell interactions with *Mycobacterium tuberculosis*-infected macrophages in rhesus macaques. *Mucosal Immunol* 11 (2): 462-473. DOI: 10.1038/mi.2017.60.
- Klinkenberg E, Floyd S, Shanaube K, Mureithi L, Gachie T, de Haas P, Kosloff B, Dodd PJ, Ruperez M, Wapamesa C, Burnett JM, Kalisvaart N, Kasese N, Vermaak R, Schaap A, Fidler S, Hayes R, Ayles H. 2023. Tuberculosis prevalence after 4 years of population-wide systematic TB symptom screening and universal testing and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: A cross-sectional survey (TREATS). *PLoS Med* 20 (9): e1004278. DOI: 10.1371/journal.pmed.1004278.
- Kopitar-Jerala N. 2017. The role of interferons in inflammation and inflammasome activation. *Front Immunol* 8: 873. DOI: 10.3389/fimmu.2017.00873.
- Kouhpayeh HR, Taheri M, Baziboroon M, Naderi M, Bahari G, Hashemi M. 2016. CCL5 rs2107538 polymorphism increased the risk of tuberculosis in a sample of Iranian population. *Prague Med Rep* 117 (2-3): 90-97. DOI: 10.14712/23362936.2016.9.
- Li C, Lu SC, Hsieh PS, Huang YH, Huang HI, Ying TH, Shieh B. 2005. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. *Intl J Immunogenet* 32 (2): 99-106. DOI: 10.1111/j.1744-313X.2005.00498.x.
- Liu S, Liu N, Wang H, Zhang X, Yao Y, Zhang S, Shi L. 2021. CCR5 promoter polymorphisms associated with pulmonary tuberculosis in a Chinese Han population. *Front Immunol* 11: 544548. DOI: 10.3389/fimmu.2020.544548.
- Ma J, Zhao S, Gao X, Wang R, Liu J, Zhou X, Zhou Y. 2021. The roles of inflammasomes in host defense against *Mycobacterium tuberculosis*. *Pathogens* 10 (2): 120. DOI: 10.3390/pathogens10020120.
- Ogishi M, Yang R, Rodriguez R et al. 2022. Inherited human ITK deficiency impairs IFN- $\gamma$  immunity and underlies tuberculosis. *J Exp Med* 220 (1): e20220484. DOI: 10.1084/jem.20220484.
- Torres ACMBG, Leite N, Tureck LV, de Souza RLR, Titski ACK, Milano-Gai GE, Lazarotto L, da Silva LR, Furtado-Alle L. 2019. Association between Toll-like receptors (TLR) and NOD-like receptor (NLR) polymorphisms and lipid and glucose metabolism. *Gene* 685: 211-221. DOI: 10.1016/j.gene.2018.11.065.
- Yan S, Shen H, Lian Q, Jin W, Zhang R, Lin X, Gu W, Sun X, Meng G, Tian Z, Chen ZW, Sun B. 2018. Deficiency of the AIM2-ASC signal uncovers the STING-driven overreactive response of type I IFN and reciprocal depression of protective IFN- $\gamma$  immunity in mycobacterial infection. *J Immunol* 200: 1016-1026. DOI: 10.4049/jimmunol.1701177.
- Yang Y, Zhou X, Kouadir M, Shi F, Ding T, Liu C, Liu J, Wang M, Yang L, Yin X, Zhao D. 2013. The AIM2 inflammasome is involved in macrophage activation during infection with virulent *Mycobacterium bovis* strain. *J Infect Dis* 208: 1849-1858. DOI: 10.1093/infdis/jit347.
- Zhang Q, Sun J, Wang Y, He W, Wang L, Zheng Y, Wu J, Zhang Y, Jiang X. 2017. Antimycobacterial and anti-inflammatory mechanisms of baicalin via induced autophagy in macrophages infected with *Mycobacterium tuberculosis*. *Front Microbiol* 8: 2142. DOI: 10.3389/fmicb.2017.02142.
- Zhou J, Lv J, Carlson C, Liu H, Wang H, Xu T, Wu F, Song C, Wang X, Wang T, Qian Z. 2021. Trained immunity contributes to the prevention of *Mycobacterium tuberculosis* infection, a novel role of autophagy. *Emerg Microbes Infect* 10 (1): 578-588. DOI: 10.1080/22221751.2021.1899771.